187 related articles for article (PubMed ID: 37481515)
1. Hepatic arterial infusion in combination with systemic chemotherapy in patients with hepatic metastasis from colorectal cancer: a randomized phase II study - (NCT05103020) - study protocol.
Kim JS; Kim H; Lee SY; Han YD; Han K; Min BS; Kim MD; Won JY; Beom SH; Shin SJ; Kim HS; Han DH; Ahn JB
BMC Cancer; 2023 Jul; 23(1):691. PubMed ID: 37481515
[TBL] [Abstract][Full Text] [Related]
2. Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol.
Boilève A; Maillard A; Wagner M; Dromain C; Laurent C; Dupont Bierre E; Le Sourd S; Audemar F; Ulusakarya A; Guerin-Meyer V; Smisth D; Pezzella V; De Baere T; Goere D; Gelli M; Taieb J; Boige V
BMC Cancer; 2020 Jan; 20(1):74. PubMed ID: 32000724
[TBL] [Abstract][Full Text] [Related]
3. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
4. Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.
Ghiringhelli F; Vincent J; Bengrine L; Borg C; Jouve JL; Loffroy R; Guiu B; Blanc J; Bertaut A
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2357-2363. PubMed ID: 31273511
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
Boilève A; De Cuyper A; Larive A; Mahjoubi L; Najdawi M; Tazdait M; Gelli M; Tselikas L; Smolenschi C; Malka D; Pignon JP; Ducreux M; Boige V
Eur J Cancer; 2020 Oct; 138():89-98. PubMed ID: 32871526
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.
Pernot S; Pellerin O; Mineur L; Monterymard C; Smith D; Lapuyade B; Gallois C; Khemissa Akouz F; De Baere T; Tougeron D; Thirot-Bidault A; Audemar F; Simon M; Lecaille C; Louafi S; Lepage C; Ducreux M; Taieb J
Dig Liver Dis; 2022 Mar; 54(3):324-330. PubMed ID: 35027324
[TBL] [Abstract][Full Text] [Related]
7. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.
Kemeny NE; Melendez FD; Capanu M; Paty PB; Fong Y; Schwartz LH; Jarnagin WR; Patel D; D'Angelica M
J Clin Oncol; 2009 Jul; 27(21):3465-71. PubMed ID: 19470932
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure.
Sato Y; Inaba Y; Ura T; Nishiofuku H; Yamaura H; Kato M; Takahari D; Tanaka T; Muro K
J Gastrointest Cancer; 2018 Jun; 49(2):132-137. PubMed ID: 28058527
[TBL] [Abstract][Full Text] [Related]
9. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI
J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
Kemeny N; Jarnagin W; Paty P; Gönen M; Schwartz L; Morse M; Leonard G; D'Angelica M; DeMatteo R; Blumgart L; Fong Y
J Clin Oncol; 2005 Aug; 23(22):4888-96. PubMed ID: 16009951
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
DʼAngelica MI; Correa-Gallego C; Paty PB; Cercek A; Gewirtz AN; Chou JF; Capanu M; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N
Ann Surg; 2015 Feb; 261(2):353-60. PubMed ID: 24646562
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial.
Malka D; Verret B; Faron M; Guimbaud R; Caramella C; Edeline J; Galais MP; Bengrine-Lefevre L; Smith D; Dupont-Bierre E; De Baere T; Goéré D; Dartigues P; Lacroix L; Boige V; Gelli M; Pignon JP; Ducreux M
Eur J Cancer; 2023 Dec; 195():113400. PubMed ID: 37922632
[TBL] [Abstract][Full Text] [Related]
14. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
[TBL] [Abstract][Full Text] [Related]
15. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
Satake H; Ando K; Oki E; Shimokawa M; Makiyama A; Saeki H; Tsuji A; Mori M
BMC Cancer; 2020 Nov; 20(1):1116. PubMed ID: 33203393
[TBL] [Abstract][Full Text] [Related]
16. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer.
Dutton SJ; Kenealy N; Love SB; Wasan HS; Sharma RA;
BMC Cancer; 2014 Jul; 14():497. PubMed ID: 25011439
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
Li C; Gu Y; Zhao M; Yuan Y; Wang F; Wang Z; Li W; Luo H; Chen C; Chen G; Ding P; Wu X; Lu Z; Pan Z; Xu R; He Y; Wan D; Li Y
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1079-87. PubMed ID: 25217393
[TBL] [Abstract][Full Text] [Related]
18. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis.
Volovat SR; Volovat C; Negru SM; Danciu M; Scripcariu V
J Chemother; 2016 Jun; 28(3):235-41. PubMed ID: 26018108
[TBL] [Abstract][Full Text] [Related]
20. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
